Seyedreza Ghiassi*

Assistant Professor of Faculty of Veterinary Medicine, Islamic Azad University, Branch of Garmsar, Garmsar, Iran

*Corresponding Author: Seyedreza Ghiassi, Assistant Professor of Faculty of Veterinary Medicine, Islamic Azad University, Branch of Garmsar, Garmsar, Iran.

Received: June 10, 2022; Published:

Abstract

Biomarkers of heart diseases are important in veterinary medicine because most cardiac conditions in dogs and cats are progressive, and some have a genetic basis. Biomarkers can be used either as a diagnostic tool or a therapeutic option. Several studies have been done on cardiac biomarkers, most of which investigated the role of pro-BNP and cardiac troponin I (cTnI) in heart diseases and congestive heart failure in dogs and cats‎ [15]. Novel promising biomarkers‎ [14], including Galectin-3 [‎10], heart-type fatty acid-binding protein (H-FABP) ‎[13], soluble suppression of tumorigenicity 2 (sST2)‎ [11], and micro-RNA (miRNA)‎ [12] have been recently drawn attention to their role as prognostic or therapeutic factors in cardiovascular diseases of dogs and cats. Among these, MiRNAs, as will be explained in this writing, have a more distinguished place in human and veterinary cardiology [‎12].

Keywords: Micro; RNAs; Heart; Biomarker

References

1. Bartel DP. “MicroRNAs: genomics, biogenesis, mechanism, and function”. Cell 16 (2004): 281-297.
2. Ge W., et al. “Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation”. Frontiers in Endocrinology 1 (2018): 402.
3. Nappi F., et al. “MicroRNAs in Valvular Heart Diseases: Biological Regulators, Prognostic Markers and Therapeutical Targets”. International Journal of Molecular Sciences 22 (2021): 12132.
4. Hulanicka M., et al. “Plasma miRNAs as potential biomarkers of chronic degenerative valvular disease in Dachshunds”. BMC Veterinary Research 10 (2014): 205.
5. Ro WB., et al. “Identification and Characterization of Circulating MicroRNAs as Novel Biomarkers in Dogs with Heart Diseases”. Frontiers in Veterinary Science (2021): 8.
6. Li Q., et al. “Expression Profiling of Circulating MicroRNAs in Canine Myxomatous Mitral Valve Disease”. International Journal of Molecular Sciences12 (2015): 14098-14108.
7. Wolf M., et al. “MicroRNAs em cardiologia veterinária”. In Ciencia Rural. Universidade Federal de Santa Maria 47.7 (2017).
8. Bagardi M., et al. “Circulating miR-30b-5p is upregulated in Cavalier King Charles Spaniels affected by early myxomatous mitral valve 2 disease 3”. Biorxiv (2022).
9. Sakarin S., et al. “Galectin-3 in cardiac muscle and circulation of dogs with degenerative mitral valve disease”. Journal of Veterinary Cardiology1 (2016): 34-46.
10. Lee K., et al. “Veterinary Service Evaluation of ST2 and NT-proBNP as cardiac biomarkers in dogs with heartworm disease”. Korean Journal of Veterinary Service 2 (2018): 2287-7630.
11. Lam C., et al. “Heart-fatty acid binding protein in dogs with degenerative valvular disease and dilated cardiomyopathy”. Veterinary Journal 244 (2019): 16-22.
12. Sipos B., et al. “Promising novel biomarkers in cardiovascular diseases”. In Applied Sciences (Switzerland). MDPI AG 11.8 (2021).
13. Boswood A. “Biomarkers in cardiovascular disease: Beyond natriuretic peptides”. Journal of Veterinary Cardiology 1 (2019).
14. Steudemann C., et al. “Detection and comparison of microRNA expression in the serum of Doberman Pinschers with dilated cardiomyopathy and healthy controls”. BMC Veterinary Research (2013): 9.
15. Ro WB., et al. “Expression Profile of Circulating MicroRNAs in Dogs with Cardiac Hypertrophy: A Pilot Study”. Frontiers in Veterinary Science (2021): 8.
16. McAlexander MA., et al. “Comparison of Methods for miRNA Extraction from Plasma and Quantitative Recovery of RNA from Cerebrospinal Fluid”. Frontiers in Genetics (2013): 4.
17. Wright K., et al. “Comparison of methods for miRNA isolation and quantification from ovine plasma”. Scientific Reports1 (2020).
18. Witwer KW., et al. “Standardisation of sample collection, isolation and analy-sis methods in extracellular vesicle research: an ISEV position paper”. Journal of Extracellular Vesicles (2013).
19. Nappi F., et al. “Preprints. NOT PEER-REVIEWED.
20. Chen C., et al. “MicroRNA as a Therapeutic Target in Cardiac Remodeling”. BioMed Research International 2017 (2017): 1278436.
21. Cheng Y., et al. “MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy?” The American Journal of Pathology6 (2007): 1831-1840.
22. Wang J., et al. “MicroRNA-24 regulates cardiac fibrosis after myocardial infarction”. Journal of Cellular and Molecular Medicine9 (2012): 2150-2160.
23. He M., et al. “GTPase Activating Protein (Sh3 Domain) Binding Protein 1 Regulates the Processing of MicroRNA-1 during Cardiac Hypertrophy”. PloS One12 (2015): e0145112.
24. Alikunju S., et al. “G3bp1 - microRNA-1 axis regulates cardiomyocyte hypertrophy”. Cellular Signalling 91 (2022): 110245.
25. Diniz GP., et al. “MicroRNA-1 overexpression blunts cardiomyocyte hypertrophy elicited by thyroid hormone”. Journal of Cellular Physiology12 (2017): 3360-3368.
26. Zhang Y., et al. “MicroRNA Profiling of Atrial Fibrillation in Canines: MiR-206 Modulates Intrinsic Cardiac Autonomic Nerve Remodeling by Regulating SOD1”. PLoS One3 (2015): e0122674.

Citation

Citation: Seyedreza Ghiassi. “Micro-RNAs in the Heart: More than a Biomarker". Acta Scientific Veterinary Sciences 4.7 (2022): 00-00.

Copyright

Copyright: © 2022 Seyedreza Ghiassi. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.